Chronic Primary Mitral Regurgitation

Similar documents
Mitral Valve prolapse: What s new? Which indications of early surgery? Input of new 2017 ESC/EACTS guidelines. Christophe Tribouilloy Amiens, France

What is the Role of Surgical Repair in 2012

Primary Mitral Regurgitation

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017

Quality Outcomes Mitral Valve Repair

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan

Les valvulopathies en sourdine: la valve mitrale Quoi faire devant une régurgitation mitrale sévère asymptomatique de type dégénérative?

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Severe left ventricular dysfunction and valvular heart disease: should we operate?

Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F.

DECISION MAKING DEL CARDIOCHIRURGO NELL INSUFFICIENZA MITRALICA: ISTRUZIONI D USO D CARDIOLOGO

Asymptomatic Valvular Disease:

Assessing Function by Echocardiography in VHD Asymptomatic Severe Organic MR. Dr. Julien Magne, PhD Sart Tilman Liège, BELGIUM

Minimally Invasive Mitral Valve Repair: Indications and Approach

Advanced Evaluation of Left Ventricular Function in Degenerative MR. Dr Julien Magne, PhD University of Liege, CHU Sart Tilman, Liege, Belgium

Catheter-based mitral valve repair MitraClip System

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL

Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention

Mitral Regurgitation

Clinical Outcome of Tricuspid Regurgitation. David Messika-Zeitoun

Exercise Pulmonary Hypertension predicts the Occurrence of Symptoms in Asymptomatic Degenerative Mitral Regurgitation

Load and Function - Valvular Heart Disease. Tom Marwick, Cardiovascular Imaging Cleveland Clinic

Επιδιόπθωζη μιηποειδικήρ ζςζκεςήρ ζε ππόπηωζη ή πήξη γλωσίνων. Βαζίλειορ Σασπεκίδηρ Επιμεληηήρ Β Καπδιολογίαρ Γ.Ν. Παπαγεωπγίος

How does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? NO DISCLOSURE

Late secondary TR after left sided heart disease correction: is it predictibale and preventable

Valvular Guidelines: The Past, the Present, the Future

Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

Low Gradient Severe? AS

Spotlight on Valvular Heart Disease Guidelines

Percutaneous Repair for MR:

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid

Evaluation of the Right Ventricle and Risk Stratification for Sudden Cardiac Death

The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD

Mitral Valve Prolapse and Sudden Death. JF Avierinos Hôpital Timone Marseille January 27th, 2017

Organic mitral regurgitation

Ann Thorac Cardiovasc Surg 2015; 21: Online April 18, 2014 doi: /atcs.oa Original Article

Candice Silversides, MD Toronto Congenital Cardiac Centre for Adults University of Toronto Toronto, Canada

Steven F Bolling Professor of Cardiac Surgery University of Michigan

Severe aortic stenosis should be operated before symptom onset CONTRA. Helmut Baumgartner

J Cardiovasc Med 2012, 13: Received 19 October 2011 Revised 8 November 2011 Accepted 29 November 2011

2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease

Prognostic Impact of FMR

Cases of mitral valve causing mitral regurgitation: the MV prolapse spectrum CASE

Current status: Percutaneous mitral valve therapy

LEFT BUNDLE BRANCH BLOCK- BENIGN OR A HARBINGER OF HEART FAILURE? PROGNOSTIC INDICATOR?

I have financial relationships to disclose Honoraria from: Edwards

Early Surgery in Asymptomatic Severe Aortic Stenosis Pros and Cons

«Paradoxical» low-flow, low-gradient AS with preserved LV function: A Silent Killer

How atrial fibrillation should be treated in the heart failure patient?

Management of the Female Pa4ent with a Cardiac Murmur

SONOGRAPHER & NURSE LED VALVE CLINICS

CARDIOLOGY GRAND ROUNDS

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Valvular Intervention

Surgical AF Ablation : Lesion Sets and Energy Sources. What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan

Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας

Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome

Exercise Testing/Echocardiography in Asymptomatic AS

Role of Ablation of AF and PVCs in the Management of Heart Failure

Percutaneous mitral valve repair: current techniques and results

Objectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009

Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know

Ischemic Mitral Regurgitation

Natural History and Echo Evaluation of Aortic Stenosis

ECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction

Echocardiographic Correlates of Pulmonary Artery Systolic Pressure

Tissue Doppler and Strain Imaging

Aortic Stenosis: UPDATE Anjan Sinha, MD Krannert Institute of Cardiology

Mitral valve surgery has changed considerably in the past decades and is now indicated

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

Transcatheter Echo Guided Mitral Valve Repair with NeoChord Implantation: Results from NeoChord Independent International Registry

When is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII

A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision

Tissue Doppler and Strain Imaging

The Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?

Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco

Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC

Catheter Ablation of Atrial Fibrillation Strategy and Outcome Predictors Shih-Ann Chen MD

Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?

Mitral Valve Disease, When to Intervene

An Overview of Mainstream Structural Heart Therapies: TAVR/MitraClip/Watchman

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines

Which Type of Secondary Tricuspid Regurgitation Accompanying Mitral Valve Disease Should Be Surgically Treated?

Clinical Practice Guidelines and the Under Treatment of Concomitant AF Vinay Badhwar, MD

What Degree of MR Deserves Surgical or Transcatheter Intervention, and How Should It Be Assessed?

Devices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine

Burden of Mitral Regurgitation (MR) in the US Why is This Important?

Coronary Artery Bypass Graft: Monitoring Patients and Detecting Complications

The Ross Procedure: Outcomes at 20 Years

Valvular Regurgitation: Can We Do Better Than Colour Doppler?

Failure of Guideline Adherence for Intervention in Patients With Severe Mitral Regurgitation

Interventional solutions for atrial fibrillation in patients with heart failure

Influence of Atrial Fibrillation on Outcome Following Mitral Valve Repair

Status Of The MitraClip: Trials (EVEREST II & COAPT) & FDA

The Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream

Really Less-Invasive Trans-apical Beating Heart Mitral Valve Repair: Which Patients?

Management of Difficult Aortic Root, Old and New solutions

Transcription:

Chronic Primary Mitral Regurgitation The Case For Early Surgical Intervention William K. Freeman, MD, FACC, FASE

DISCLOSURES Relevant Financial Relationship(s) None Off Label Usage None

Watchful Waiting...... Is Looking for Trouble

Quantitative Determinants of Outcome of Asymptomatic MR Initial Patient Characteristics 456 Asymptomatic patients with MR Mean age 63 ± 14 yrs MR regurgitant volume 66 ± 40 cm 3, ERO 40 ± 27 mm 2 ; (Gr IV/IV in 54%) LVEF: 70 ± 8%, LVESD: 34 ± 6 mm Systolic PAP: 38 ± 11 mmhg Sarano ME et al: NEJM 352:875, 2005

Quantitative Determinants of Outcome of Asymptomatic MR Patient Follow-up Follow-up: 5.1 ± 2.9 yrs 5 Yr freedom from surgery: 46 ± 3% 5 Yr freedom from surgery/death: 36 ± 3% Triggers for mitral valve surgery Cardiac symptoms: 41% LVESD 40 mm: 39% Other: 20% Sarano ME et al: NEJM 352:875, 2005

Quantitative Determinants of Outcome of Asymptomatic MR Events: Cardiac Death, CHF, New Atrial Fibrillation 70 60 ERO < 20 mm 2 ERO 20-39 mm 2 ERO 40 mm 2 62±8% 50 Rate of cardiac events (%) 40 30 P<0.01 40±7% 20 10 15±4% 0 0 1 2 3 4 5 Years Sarano ME et al: NEJM 352:875, 2005

Quantitative Determinants of Outcome of Asymptomatic MR Death From Cardiac Causes Cardiac Death (%) 50 40 30 20 ERO <20 mm 2 20-39 mm 2 40 mm 2 P<0.01 36±9% 20±6% 10 0 0 1 2 3 4 5 Years 3±2% Sarano ME et al: NEJM 352:875, 2005

Waiting for Symptoms...... Is Asking for Trouble

Adjusted survival from diagnosis (%) Early Surgery vs Conservative Therapy For Severe MR Impact of Preoperative Symptoms 100 NYHA I-II 84 NYHA III-IV 80 69 60 67 40 47 20 Early surgery Conservative Rx P < 0.02 0 0 2 4 6 8 10 Years Ling et al: Circulation 1997; 96: 1819 0 2 4 6 8 10 Years

Cardiopulmonary Exercise Testing in Asymptomatic MR: Is the Patient Truly Asymptomatic? 134 Asymptomatic patients; 63 ± 14 yrs MR regurgitant volume 68 ± 24 cm 3, ERO 35 ± 14 mm 2 ; LVEF 73±6% Reduced functional capacity (<84% predicted) related to MR in 19% Peak VO 2 22 ± 5 (74 ± 8% Predicted) Messika-Zeitoun D, et al. JACC 2006; 47: 2521

Patients with cardiac events or surgery (%) Cardiopulmonary Exercise Testing in Asymptomatic MR Events: Death, Heart Failure, Surgery, AFib 100 80 60 Functional capacity Reduced Normal 40 20 0 P=0.001 0 1 2 3 Years Messika-Zeitoun et al: JACC 47:2521, 2006

Asymptomatic MR: Exercise Induced Pulmonary Hypertension Is the Patient Truly Asymptomatic? 49 Asymptomatic patients with MR MR ERO 0.40 ± 0.14 cm 2, RVSP 30 ± 7 mmhg LVEF 67 ± 7 %, LVESD 31 ± 6 mm Symptom limited exercise echo VO 2 stress 24% with <80% functional aerobic capacity (FAC) Exercise induced pulmonary hypertension (RVSP 60 mmhg) the strongest multivariate predictor of poor FAC and onset of symptoms Suzuki K, et al. J Cardiol 2015; 66: 246

Sensitivity Asymptomatic MR: Exercise Induced Pulmonary Hypertension Is the Patient Truly Asymptomatic? 1.0 0.8 0.6 0.4 0.2 Systolic PAP Exercise* C = 0.88 Exercise Resting C = 0.52 *Adjusted for age and gender 0.0 0.0 0.2 0.4 0.6 0.8 1.0 1-specificity Suzuki K, et al. J Cardiol 2015; 66: 246

Symptom-free survival Asymptomatic MR: Exercise Induced Pulmonary Hypertension Is the Patient Truly Asymptomatic? 1.0 0.8 0.6 Patients at Risk 0.4 0.2 0.0 No Exercise Induced Pulmonary HTN Exercise Induced Systolic PAP 60 mmhg 0 5 10 15 20 25 Months P=0.003 31 31 31 30 29 29 18 14 11 11 11 11 Suzuki K, et al. J Cardiol 2015; 66: 246

Asymptomatic MR: Exercise Induced Pulmonary Hypertension Post-Op Events: Heart Failure, Stroke, Death 104 Patients; mean age 64 ± 12 yrs MR ERO 0.40 ± 0.07 cm 2, RVSP 36 ± 7 mmhg LVEF 71 ± 5 %, LVESD 34 ± 6 mm Preoperative exercise echo: 58% of patients had exercise induced pulmonary HTN (RVSP 60 mmhg) Mitral surgery for isolated primary MR directed by ACC/AHA guideline triggers Magne J, et al. Heart 2015; 101: 391

Postop event-free survival (%) Asymptomatic MR: Exercise Induced Pulmonary Hypertension Post-Op Events: Heart Failure, Stroke, Death 100 90±4 90±4 90±4 90±4 80 60 85±5 79±5 67±7 Patients at Risk 40 20 0 No Exercise Pulmonary HTN Exercise Pulmonary HTN 37±14 0 12 24 36 48 60 72 84 96 Months Follow-up 43 37 26 6 2 59 48 37 15 4 P=0.003 Magne J, et al. Heart 2015; 101: 391

And we must be wary... of the ultimate end-point

Sudden Death in Severe MR Due to Flail Leaflet 348 Patients with flail MV leaflet Mean age: 67 ± 12 yrs; 48 ± 41 mo. F/U Under medical therapy: 99 deaths Sudden death: 25 patients (7.2%) Sudden death multivariate predictors : NYHA functional class LVEF (mean initial EF 63 ± 10%) Atrial fibrillation Grigioni F, et al. JACC 1999; 34:2078

Incidence (%) Sudden Death in Severe MR Due to Flail Leaflet 100 80 Total mortality Cardiac mortality Sudden death 60 40 20 0 53±5 43±5 19±4 0 1 2 3 4 5 6 7 8 9 10 Years after diagnosis Grigioni F, et al. JACC 1999; 34:2078

Sudden Death in Severe MR Due to Flail Leaflet: Relation to NYHA Functional Class 10 8 7.8 ± 3.2 Yearly rate of sudden death (%/year) 6 4 3.1 ± 1.0 2 0 1.0 ± 0.3 NYHA I NYHA II NYHA III-IV Grigioni F, et al. JACC 1999; 34:2078

Sudden Death in Severe MR Due to Flail Leaflet: Relation to LVEF 15 12.7 ± 5.2 10 5 1.5 ± 0.4 0.9 ± 0.6 0 60 50-59 < 50 LVEF (%) Grigioni F, et al. JACC 1999; 34:2078

Sudden Death in Severe MR Due to Flail Leaflet: Sinus Rhythm vs. Atrial Fibrillation 10 8 6 4.9 ± 1.6 4 2 0 1.3 ± 0.3 Sinus Rhythm Atrial Fibrillation Grigioni F, et al. JACC 1999; 34:2078

Sudden Death in Severe MR Due to Flail Mitral Leaflet In patients NYHA Class I-II, in sinus rhythm, LVEF 60%, and no history of CAD: Rate of sudden death = 0.8% / yr Grigioni F, et al. JACC 1999; 34:2078

If There Are No Randomized Controlled Trials...... Perform a Meta - Analysis

Early Surgical Intervention vs. Watchful Waiting for Asymptomatic MR A Meta-Analysis Observational studies; tertiary referral Asymptomatic patients without Class I Guideline triggers for surgery All primary (degenerative) MR etiology All included a watching waiting cohort Goldstone AB, et al. Ann Cardiothorac Surg 2015; 4: 220

Timing of Surgical Intervention for Asymptomatic MR (No Class I Trigger) All Cause Mortality (1,823 Patients) Study HR Lower limit Upper limit Z P HR (95% CI) Kang (2014) 0.509 0.241 1.076-1.769 0.077 Suri (2103) 0.520 0.346 0.781-3.149 0.002 Montant (2009) 0.190 0.093 0.388-4.566 0.000 0.38 0.206 0.708-3.057 0.002 0.1 0.2 0.5 1 2 5 10 Favors early surgery Favors Watchful waiting Goldstone AB, et al. Ann Cardiothorac Surg 2015; 4: 220

Timing of Surgical Intervention for Asymptomatic MR (No Class I Trigger) Mitral Repair Rate (1,631 Patients) Study HR Lower limit Upper limit Z P HR (95% CI) Kang (2014) 1.155 1.047 1.273 2.879 0.004 Suri (2013) 1.069 1.019 1.122 2.718 0.007 1.10 1.022 1.179 2.559 0.010 0.5 1 2 Favors Watchful waiting Favors early surgery Goldstone AB, et al. Ann Cardiothorac Surg 2015; 4: 220

A Stitch in Time...... Saves Nine

Surgery for MR: The Importance of Experience and Volume STS Database (13,614 MV operations) Hospital Mitral Procedures / Year 35 36-70 71-140 > 140 Operative Mortality MV Repair Rate 3.1% 2.3% 2.0% 1.1% 48% 55% 65% 78% Gammie JS, et al. Circulation 2007; 115: 881

Elective Mitral Repair For Severe MR vs. Risk of Sudden Death Risk of Sudden Death (0.8%/yr) Operative Mortality* (0-0.5%) * High volume, tertiary referral surgical centers Grigioni F, et al. JACC 1999; 34:2078 Kang DH et al. Circulation 2009; 119:797 DeBonis M, et al Eur Heart J 2013;34;13 Suri RM et al. JAMA 2013; 310:609 Yazdchi F, et al. Ann Thorac Surg 2015; 99:1992

Are we delaying surgery too long.... with the current guideline triggers to intervention?

Current (2014) Guideline Indications Triggering Surgery for Severe MR Is There an Outcome Penalty? 1,512 Patients: Surgery for Primary MR Class I Triggers: Class II Triggers: Class II Triggers: Cardiac Symptoms, LVEF < 60%, or LVESD > 40 mm (n = 794) Clinical complications: New AFib, or pulmonary HTN (n = 195) Early Asymptomatic: Gr 4/4 MR, High probability of MV Repair only (n = 523) Sarano ME, et al. J Thorac Cardiovasc Surg 2015; 150: 50 Nishimura RA, CM Otto, et al. JACC 2014; 63: e57

Guideline Indication Triggers for Surgery in Severe MR: Impact on Post-Op Survival Post-op survival (%) Patients at Risk 100 80 60 40 20 0 Triggers 94±1 87±2 84±1 86±2 73±3 64±2 Class II - High Prob Repair Class II - New AFib, PHTN Class I Sxs, LVEF, LVESD 70±3 53±4 42±2 P<0.0001 61±5 40±7 27±3 0 5 10 15 20 Years 523 488 403 68 6 195 168 127 38 3 794 664 461 135 13 Sarano ME, et al. J Thorac Cardiovasc Surg 2015; 150: 50

Guideline Indication Triggers for Surgery in Severe MR: Impact on Outcome 80 60 40 20 0 Patients at Risk Heart Failure Triggers Class II - High Prob Repair Class II - New AFib, PHTN Class I Sxs, LVEF, LVESD P<0.0001 14±1 10±2 3±1 Death or Heart Failure P<0.0001 0 5 10 15 0 5 10 15 Years 24±2 21±3 6±1 35±2 27±4 15±3 24±2 20±3 Years 46±2 39±4 65±2 55±4 478 383 61 478 382 61 155 110 33 155 110 33 592 383 107 592 383 107 7±1 19±2 37±3 Sarano ME, et al. J Thorac Cardiovasc Surg 2015; 150: 50

Overall survival (%) Left Ventricular End-Systolic Dimension (LVESD) in Severe MR MIDA Database: 739 Patients with Flail Lealflet 1.0 Watchful Waiting Surgical Intervention 0.8 0.6 0.4 0.2 0.0 LVESD (mm) <40 40 0 2 4 6 8 10 Years 64±5 48±10 P<0.001 72±3 64±5 P=0.04 0 2 4 6 8 10 Years Tribouilloy et al: JACC 2009; 54:1961

Left Ventricular End-Systolic Dimension (LVESD) in Severe MR Risk of Mortality With Watchful Waiting Risk Ratio of Death 10 3.2 1.0 Indexed cut-point for increased mortality: LVESD 22 mm/m 2 0.3 20 25 30 35 40 45 50 LVESD (mm) Tribouilloy et al: JACC 2009; 54:1961

Severe MR: The Fallacy of Normal Preoperative LV Function LVEF (%) Post-Op LV Ejection Fraction 50% (n = 1,391) < 50% (n = 314) Pre-Op Post-Op LVESD (mm) Pre-Op Post-Op 66.8 ± 4.8 65.3 ± 4.0 59.2 ± 5.8 41.8 ± 6.2 34.2 ± 4.6 37.7 ± 4.4 33.4 ± 5.1 41.9 ± 5.4 p<0.001 p<0.001 p<0.001 Quintana E, et al. J Thorac Cardiovasc Surg 2014; 148; 2752

Severe MR: Predictors of Early Postoperative LVEF < 40% * OR (± 95% CI) RVSP > 49 mmhg 4.40 (2.35-8.23) LVESD > 36 mm 6.46 (3.31-13.61) 1 2 3 4 5 6 7 8 9 10 11 12 13 * Post-Operative Death HR = 1.74 (1.03-2.92) Quintana E, et al. J Thorac Cardiovasc Surg 2014; 148; 2752

Severe Primary Mitral Regurgitation: The Case for Early Surgical Intervention Conclusions Unoperated severe MR has serious clinical consequences, even if asymptomatic Clinical symptom status is often unreliable Stress testing discriminates elusive functional status and prognosticates Early surgical intervention improves outcome Selection of surgical center and surgeon is critical Current ACC/AHA guideline triggers to surgery may delay intervention, resulting in suboptimal outcome Why wait for the inevitable, and increase patient risk?